Flagship Pioneering has announced that ProFound Therapeutics and Quotient Therapeutics have entered into separate feasibility agreements with GSK to discover and validate novel treatments for respiratory and liver diseases. These agreements are the first company-focused deals under the framework collaboration between Flagship and GSK, combining GSK’s disease area expertise and development capabilities with Flagship’s ecosystem of bioplatform companies.

“Flagship Pioneering and GSK have a shared mission to accelerate the development of breakthrough medicines for patients with the greatest unmet needs by combining innovative new technologies with deep drug development expertise,” Paul Biondi, managing partner, Flagship Pioneering, said. “These agreements bring together two pioneering approaches to advance innovative treatments for respiratory and liver diseases, and to identify novel and differentiated targets that may alter the course of disease.”

ProFound Therapeutics will leverage its ProFoundry Platform, which integrates advanced protein detection technologies, targeted high-throughput functional validation methods, and computational tools, to explore the expanded human proteome. This includes previously unrecognized proteins encoded by the human genome that may serve as potential drug targets. Through two separate agreements, ProFound will advance discoveries to characterise novel proteins with strong genetic associations with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), examining their therapeutic relevance.

Quotient Therapeutics will use its Somatic Genomics platform, which studies the natural, acquired genetic diversity present in patients, to identify disease-causal drug targets. Three separate agreements enable Quotient to apply its technology to COPD, IPF, and metabolic dysfunction-associated steatohepatitis (MASH), potentially unlocking new therapeutic strategies across these conditions.

Under the terms of the agreements, if GSK elects to progress the programs, ProFound and Quotient will advance their respective discoveries through key preclinical activities. GSK will then have the exclusive option to move the programs into clinical studies, supporting the development of differentiated treatments.

These agreements highlight the combination of platform-driven innovation with disease-focused expertise, reflecting Flagship’s approach of integrating emerging biotechnologies with strategic collaborations to accelerate drug discovery. By leveraging novel modalities such as the expanded human proteome and somatic genomics, these collaborations aim to uncover previously unrecognized targets with the potential to transform treatment options for respiratory and liver diseases.